MYO · Myomo, Inc.
$1.72
+0.26 (+17.81%)
At close · Aug 14
Market Cap
$68.13M
Shares
39.61M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Paul R. Gudonis | Chief Executive Officer | $1,201,183 |
| David A. Henry | Chief Financial Officer | $690,242 |
| Harry Kovelman | Chief Medical Officer | $607,798 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Paul R. Gudonis | Chief Executive Officer | $1,240,467 |
| David A. Henry | Chief Financial Officer | $784,166 |
| Harry Kovelman | Chief Medical Officer | $695,112 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Paul R. Gudonis | Chief Executive Officer | $663,900 |
| David A. Henry | Chief Financial Officer | $478,898 |
| Harry Kovelman | Chief Medical Officer | $478,374 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Paul R. Gudonis | Chief Executive Officer | $526,043 |
| David A. Henry | Chief Financial Officer | $365,642 |
| Harry Kovelman | Chief Medical Officer | $340,024 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Paul R. Gudonis | Chief Executive Officer | $957,572 |
| David A. Henry | Chief Financial Officer | $618,210 |
| Harry Kovelman | Chief Medical Officer | $447,132 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Thomas F. Kirk | Class III director | Appointed | 2026-06-26 |
| Paul R. Gudonis | Class III director | Appointed | 2026-06-26 |
| Joseph M. Manko Jr. | Class I director | Appointed | 2026-05-13 |
| William J. Febbo | Class II director | Appointed | 2026-04-16 |
| Heather Getz | Class II director | Appointed | 2024-03-28 |
| Yitzchak Jacobovitz | Class II director | Appointed | 2023-01-30 |
Key facts
CIK
1369290
CUSIP
62857J201
13F (30d)
75 filings
73 filers
Visit website
Investor relations